MapLight Therapeutics CMO sells 47,158 shares

MapLight Therapeutics, Inc. reported that Chief Medical Officer Erin Pennock Foff sold a total of 47,158 shares of Voting Common Stock over July 15–17, 2026.

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. reported that Chief Medical Officer Erin Pennock Foff sold a total of 47,158 shares of Voting Common Stock over July 15–17, 2026. After these transactions, she directly holds 298,901 shares. Certain sales were executed under a Rule 10b5-1 trading plan adopted on December 29, 2025, while others were mandated "sell to cover" transactions to satisfy statutory tax withholding arising from vesting restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 47,158 shares

Net Sell 9 txns

Insider Foff Erin Pennock

Role Chief Medical Officer

Sold 47,158 shs ($1.73M)

Type	Security	Shares	Price	Value
Sale	Voting Common Stock F4, F9	3,656	$37.90	$139K
Sale	Voting Common Stock F4, F7	9,163	$36.46	$334K
Sale	Voting Common Stock F4, F8	5,865	$37.26	$219K
Sale	Voting Common Stock F4	19	$37.96	$721.24
Sale	Voting Common Stock F1, F2	7,155	$36.16	$259K
Sale	Voting Common Stock F1, F3	7,845	$37.04	$291K
Sale	Voting Common Stock F4, F5	4,465	$36.00	$161K
Sale	Voting Common Stock F4, F6	8,972	$36.99	$332K
Sale	Voting Common Stock F4	18	$37.54	$675.72

Holdings After Transaction: Voting Common Stock — 298,901 shares (Direct)

Footnotes (9)

1. F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.70 to $36.685 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.701 to $37.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.5338 to $36.5273 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.53 to $37.405 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.9075 to $36.9013 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.9082 to $37.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
9. F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.49 to $37.925 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 47,158 shares Post-transaction holdings: 298,901 shares Sale date range: July 15–17, 2026 +3 more

6 metrics

Shares sold 47,158 shares Aggregate Voting Common Stock sales reported for July 15–17, 2026

Post-transaction holdings 298,901 shares Directly held Voting Common Stock after the final reported sale

Sale date range July 15–17, 2026 Dates of the reported open-market or private stock sales

Weighted-average sale price example $36.16 per share Weighted-average price for 7,155 shares sold on July 15, 2026

Weighted-average sale price example $37.04 per share Weighted-average price for 7,845 shares sold on July 15, 2026

Rule 10b5-1 plan adoption date December 29, 2025 Date the reporting person adopted the Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, weighted average price, sell to cover, restricted stock units, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price. These shares..."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

sell to cover financial

"to be funded by a sell to cover transaction and does not represent..."

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

restricted stock units financial

"tax withholding obligations in connection with the vesting of the restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

statutory tax withholding obligations financial

"shares required to be sold to cover the statutory tax withholding obligations..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock transactions did MapLight Therapeutics (MPLT) report in this Form 4?

MapLight Therapeutics reported that Chief Medical Officer Erin Pennock Foff sold 47,158 shares of Voting Common Stock between July 15 and 17, 2026. The sales were reported as open-market or private transactions with several weighted-average prices disclosed via detailed footnotes.

How many MapLight Therapeutics (MPLT) shares does the CMO hold after these transactions?

Following the reported sales, Chief Medical Officer Erin Pennock Foff directly holds 298,901 shares of MapLight Therapeutics Voting Common Stock. This post-transaction holding figure is disclosed in the Form 4 for each transaction line and reflects her remaining direct ownership position.

At what prices were MapLight Therapeutics (MPLT) shares sold in the reported transactions?

The Form 4 lists per-share prices such as $36.16, $37.04, and others, many described as weighted average prices. Footnotes state that underlying trades occurred in ranges from $35.5338 up to $37.925 per share across multiple executions.

Were the MapLight Therapeutics (MPLT) insider sales discretionary or under a plan?

Some transactions were made under a Rule 10b5-1 trading plan adopted on December 29, 2025, as disclosed in a footnote. Other sales are identified as mandatory “sell to cover” transactions to satisfy statutory tax withholding from vesting restricted stock units.

Who is the reporting person in MapLight Therapeutics (MPLT) Form 4 and what is their role?

The reporting person is Erin Pennock Foff, who serves as Chief Medical Officer of MapLight Therapeutics. The Form 4 details her recent sales of Voting Common Stock, the prices involved, and her resulting direct share ownership after the transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 09:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foff Erin Pennock

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	07/15/2026		S(1)		7,155	D	$36.16(2)	338,904	D
Voting Common Stock	07/15/2026		S(1)		7,845	D	$37.04(3)	331,059	D
Voting Common Stock	07/15/2026		S		4,465(4)	D	$36(5)	326,594	D
Voting Common Stock	07/15/2026		S		8,972(4)	D	$36.99(6)	317,622	D
Voting Common Stock	07/15/2026		S		18(4)	D	$37.54	317,604	D
Voting Common Stock	07/16/2026		S		9,163(4)	D	$36.46(7)	308,441	D
Voting Common Stock	07/16/2026		S		5,865(4)	D	$37.26(8)	302,576	D
Voting Common Stock	07/16/2026		S		19(4)	D	$37.96	302,557	D
Voting Common Stock	07/17/2026		S		3,656(4)	D	$37.9(9)	298,901	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.70 to $36.685 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.701 to $37.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.5338 to $36.5273 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.53 to $37.405 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.9075 to $36.9013 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.9082 to $37.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.49 to $37.925 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)